A Phase III, Multicenter, Open-labeded Study To Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients
[Translation] Phase III study to evaluate the efficacy and safety of co-administration of volaprevir, emitasvir phosphate and ribavirin in subjects with chronic hepatitis C genotype 1
To evaluate the efficacy and safety of Volaprevir Capsules, Emitasvir Phosphate Capsules and Ribavirin for 12 weeks in subjects with chronic hepatitis C virus genotype 1.
[Translation] Phase III study to evaluate the efficacy and safety of co-administration of volaprevir, emitasvir phosphate and ribavirin in subjects with chronic hepatitis C genotype 1
To evaluate the efficacy and safety of Volaprevir Capsules, Emitasvir Phosphate Capsules and Ribavirin for 12 weeks in subjects with chronic hepatitis C virus genotype 1.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.